XOMA and LAVA amend purchase agreement with lower cash offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025 11:45 AM EDT- Amendment includes finalized cash amount and updated CVR terms for tender offer
- LAVA announces new date for extraordinary general meeting of shareholders
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (XOMA Royalty) (Nasdaq: XOMA) and LAVA Therapeutics N.V. (LAVA) (Nasdaq: LVTX) today announced that they have reached an agreement to amend their previously announced definitive share purchase agreement (the Purchase Agreement, and such amendment, the Amendment). Â
Under the Amendment, LAVA... More
